Description

Aclasta (Zoledronic Acid) Solution for Infusions 5 mg/100 ml Vial №1

Ingredients:

Each vial contains 5 mg of zoledronic acid in 100 ml of solution.

Dosage:

The recommended dosage is 5 mg infused over at least 15 minutes. Dosage adjustments may be necessary based on renal function.

Indications:

Aclasta is indicated for the treatment of osteoporosis in postmenopausal women and in men at increased risk of fractures. It is also used for the prevention of skeletal-related events in patients with bone metastases.

Contraindications:

Do not use Aclasta if you have hypocalcemia or a known hypersensitivity to zoledronic acid. Caution is advised in patients with renal impairment.

Directions:

A healthcare professional should administer Aclasta via intravenous infusion. Adequate hydration should be ensured prior to administration to reduce the risk of renal toxicity.

Scientific Evidence:

Aclasta, containing zoledronic acid, has been extensively studied for its efficacy in the treatment of osteoporosis and prevention of skeletal-related events in cancer patients. Clinical trials have shown that zoledronic acid significantly reduces the risk of fractures in postmenopausal women with osteoporosis and improves bone mineral density.

Additional Information:

In addition to its primary indications, zoledronic acid has also been investigated for its potential role in the treatment of Paget’s disease of bone and hypercalcemia of malignancy. Studies have demonstrated the long-term safety and efficacy of zoledronic acid in these conditions, making it a versatile treatment option in the field of bone health.

Overall, Aclasta (zoledronic acid) solution for infusions 5 mg/100 ml vial №1 offers a potent and well-established treatment option for conditions affecting bone health, backed by robust scientific evidence and clinical trials.